Chronic GvHD-associated @entity11534 and XXXX .

@entity1 @entity2396 @entity11534 @entity230
UNASSIGNED: @entity11534 is a rare manifestation of chronic GvHD (cGvHD). No risk factors or laboratory changes associated with this syndrome have been recognized to date, and outcomes have not been described in a large series. We searched our institutional database for @entity1 undergoing allogeneic hematopoietic cell transplant identified as having @entity11534 or @entity2396 . Laboratory studies from prior to diagnosis, at diagnosis and post diagnosis of @entity11534 , as well as outcomes from invasive procedures were included. Twenty @entity1 met criteria for cGvHD-associated @entity11534 , and all but three @entity1 had a prior diagnosis of cGvHD. Fifteen were male, and the complication occurred in the setting of immunosuppressant taper in 12 cases. Ten @entity1 required invasive interventions, including pericardial window or stripping. A significant increase in blood monocytes and decrease in serum albumin were identified at diagnosis compared with pre-diagnosis. Out of 20 @entity1 , 17 were treated with @entity230 , with 12 demonstrating a complete response. These data suggest that cGvHD-associated @entity11534 occurs mainly in the setting of treated as opposed to de novo cGvHD and biomarkers associated with the syndrome include a decrease in albumin and an increase in absolute monocyte count. Outcome data from larger series are required to better understand the optimal management of this rare complication.Bone Marrow Transplantation advance online publication, 11 May 2015; doi:10.1038/bmt.2015.105.
